Product Information
ROWEEPRA 500 MG TABLET is a generic product labeled by OWP Pharmaceuticals, Inc., priced at $0.0736 per EA under NDC 69102010501. Its NADAC has been published 291 times since Mar 10, 2021.
FDA first approved this application on Jan 15, 2009. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
500 mg/1
Manufacturer
OWP Pharmaceuticals, Inc.NDC
69102010501
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LEVETIRACETAMApproval Type
Generic (ANDA)
FDA Application
ANDA078858FDA Approved
1/15/2009
TE Code
AB
On Market Since
10/28/2020
Pharmacological Classes
Price Statistics
The NADAC for ROWEEPRA 500 MG TABLET has been published 291 times since Mar 10, 2021, and over the history we have for it it has declined 40.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0736 per EA |
|---|---|
| All-time high | $0.1251 (Aug 11, 2021) |
| All-time low | $0.0608 (Nov 20, 2024) |
| 52-week high | $0.0780 |
| 52-week low | $0.0736 |
| Median price | $0.0902 |
| Average price | $0.0903 |
| Largest weekly change | -26.6% (Nov 20, 2024) |
| Weeks tracked | 291 |
| Tracking since | Mar 10, 2021 |
Generic Alternatives
The matcher finds 20 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 2% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
OWP Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Levetiracetam market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ROWEEPRA 500 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ROWEEPRA 500 MG TABLET, manufactured by OWP Pharmaceuticals, Inc., is $0.0736 per EA (NDC 69102010501), effective Sep 30, 2026.
How has the price of ROWEEPRA 500 MG TABLET changed over time?
Over the history we have for it, the NADAC for ROWEEPRA 500 MG TABLET has declined 40.4%. It has been tracked across 291 weekly CMS publications since Mar 10, 2021.
What are the highest and lowest recorded NADAC prices for ROWEEPRA 500 MG TABLET?
Since Mar 10, 2021, the NADAC for ROWEEPRA 500 MG TABLET has ranged from a low of $0.0608 (Nov 20, 2024) to a high of $0.1251 (Aug 11, 2021), with a median of $0.0902 per EA.
Are there cheaper alternatives to ROWEEPRA 500 MG TABLET?
Yes. 20 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LEVETIRACETAM 500 MG TABLET, is $0.0720 per EA — about 2% below ROWEEPRA 500 MG TABLET.
Who manufactures ROWEEPRA 500 MG TABLET?
ROWEEPRA 500 MG TABLET (NDC 69102010501) is labeled by OWP Pharmaceuticals, Inc., and CMS classifies it as a generic product.